Identification of 3q oncogene SEC62 as a marker for distant metastasis and poor clinical outcome in invasive ductal breast cancer

Identification of SEC62 as a potential marker for 3q amplification and cellular migration in dysplastic cervical lesions

(2016) Maximilian Linxweiler et al.   BMC CANCER

Mipsagargin, a novel thapsigargin-based PSMA-activated prodrug: results of a first-in-man phase I clinical trial in patients with refractory, advanced or metastatic solid tumours

(2016) D Mahalingam et al.   BRITISH JOURNAL OF CANCER

Translocon component Sec62 acts in endoplasmic reticulum turnover during stress recovery

(2016) Fiorenza Fumagalli et al.   NATURE CELL BIOLOGY

Initial evidence for Sec62 as a prognostic marker in advanced head and neck squamous cell carcinoma

(2016) SILKE WEMMERT et al.   Oncology Letters

Effect of 3q oncogenes SEC62 and SOX2 on lymphatic metastasis and clinical outcome of head and neck squamous cell carcinomas

(2016) Florian Bochen et al.   Oncotarget

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

(2013) A. Goldhirsch et al.   ANNALS OF ONCOLOGY

Prostate-specific membrane antigen expression in tumor-associated vasculature of breast cancers

(2013) Alla Gabriella Wernicke et al.   APMIS

Targeting cell migration and the endoplasmic reticulum stress response with calmodulin antagonists: a clinically tested small molecule phenocopy of SEC62 gene silencing in human tumor cells

(2013) Maximilian Linxweiler et al.   BMC CANCER

Metastasis Dormancy in Estrogen Receptor-Positive Breast Cancer

(2013) X. H.- F. Zhang et al.   CLINICAL CANCER RESEARCH

Systematic Interrogation of 3q26 Identifies TLOC1 and SKIL as Cancer Drivers

(2013) D. Hagerstrand et al.   Cancer Discovery

Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen

(2012) A. Prat et al.   ANNALS OF ONCOLOGY

Prognostic Significance of Progesterone Receptor–Positive Tumor Cells Within Immunohistochemically Defined Luminal A Breast Cancer

(2012) Aleix Prat et al.   JOURNAL OF CLINICAL ONCOLOGY

Identification of cyclin B1 and Sec62 as biomarkers for recurrence in patients with HBV-related hepatocellular carcinoma after surgical resection

(2012) Li Weng et al.   Molecular Cancer

Engineering a Prostate-Specific Membrane Antigen-Activated Tumor Endothelial Cell Prodrug for Cancer Therapy

(2012) S. R. Denmeade et al.   Science Translational Medicine

Sec62 Bridges the Gap from 3q Amplification to Molecular Cell Biology in Non–Small Cell Lung Cancer

(2011) Maximilian Linxweiler et al.   AMERICAN JOURNAL OF PATHOLOGY

Sec62 protein level is crucial for the ER stress tolerance of prostate cancer

(2011) Markus Greiner et al.   PROSTATE

What made sesquiterpene lactones reach cancer clinical trials?

(2010) Akram Ghantous et al.   DRUG DISCOVERY TODAY

Silencing of the SEC62 gene inhibits migratory and invasive potential of various tumor cells

(2010) Markus Greiner et al.   INTERNATIONAL JOURNAL OF CANCER

Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer

(2009) Maggie C. U. Cheang et al.   JNCI-Journal of the National Cancer Institute